Tf ligand-receptor-mediated exenatide-Zn<sup>2+</sup> complex oral-delivery system for penetration enhancement of exenatide.
J Drug Target · 2018
Last updated 2026-05-28Researchers tested a new way to deliver exenatide, a peptide drug, by mouth using tiny particles called nanoparticles. By adding transferrin (a protein) and zinc ions to the particles, they found the drug was absorbed better than without these additions. The oral version reached 6.45% of the effectiveness of the injected form in early tests.
AI summary of the abstract below.
| Journal | J Drug Target, 2018 |
|---|---|
| Citations | 21 |
| Relative citation ratio | 1.04 |
| NIH percentile | 52 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Safe and effective oral delivery of peptide is a challenge. Here, we used exenatide and zinc ions (Zn) to form a complex to explore a meaningful oral-targeted drug-delivery system. Polyethylene glycol-poly(lactic acid-co-glycolic acid) (PEG-PLGA) was used to prepare nanoparticles (NPs) to escape the degradation caused by gastrointestinal enzymes. Transferrin (Tf) was used as a targeting group. PEG-PLGA-NPs and Tf-modified exenatide-Zn-loaded NPs (Tf-PEG-PLGA-NPs) were uniformly sized spheres according to transmission electron microscopy. The results of pharmacodynamic and pharmacokinetic investigations in vivo were consistent with in vitro studies using Caco-2 cells. Tf enhanced NPs transport in cell-uptake and transmembrane-transport experiments. Our results showed that the relative bioavailability of Tf-exenatide-Zn-NPs was higher than that of exenatide-Zn-NPs. The relative bioavailability of Tf-exenatide-Zn-NPs versus subcutaneous injection of exenatide was 6.45%. This was a preliminary exploration of the oral administration of exenatide, that data from which can be used for future investigations.
Verbatim abstract via PubMed 29619854 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.